Abstrakt
Knowledge of causal role of thrombocytes in pathogenesis of acute coronary syndromes led to the development of still more effective antithrombotics. It resulted in impressive lowering of incidence of recurrent ischaemic events, but at the cost of increased risk of bleeding, which worsens the patient's prognosis.
Therefore the present strategy of antithrombotic treatment considers two aspects - efficacy and safety. The main aim of the treatment is to reduce the incidence of atherothrombotic events at acceptable risk of bleeding.
The overview article contains informations on present peroral antiplatelet treatment of patients with acute coronary syndrome, advantages and limitations of recommended drugs. The goal of this overview is to present sufficient information helping a reader to choose an optimal process in an individual patient.